Zobrazeno 1 - 9
of 9
pro vyhledávání: '"329"'
Autor:
Yanmin Zhao, Lizhen Liu, Yi Chen, Ying Lu, Jian Yu, Kang Yu, He Huang, Xiaoyu Lai, Jimin Shi, Huarui Fu, Fei Gao, Baodong Ye, Lieguang Chen, Jianping Lan, Xiaolu Song, Yi Luo
Publikováno v:
Blood. 138:1825-1825
Objective Hematopoietic stem cell transplantation (HSCT) is one of the most efficient treatments for hematologic malignancies. However, relapse remains the main cause of transplant failure. In myeloid neoplasia, the long-term survival for patients wh
Autor:
Jian-Ping Zhang, Rui-Juan Sun, Peihua Lu, Junfang Yang, Xian Zhang, Yan-Li Zhao, Jingjing Li, Min Xiong, Jia-Rui Zhou, De-Yan Liu, Yue Lu, Xing-Yu Cao, Zhi-Jie Wei
Publikováno v:
Blood. 136:40-41
Introduction Current available treatments are limited once patients with B-ALL relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT). While chimeric antigen receptor (CAR) T-cell therapy offers a chance of remission, long-t
Autor:
Rohtesh S. Mehta, Gregory P. Kaufman, Elisabet E. Manasanch, Neeraj Saini, Chitra Hosing, Uday R. Popat, Qaiser Bashir, Gabriela Rondon, Elizabeth J. Shpall, Partow Kebriaei, Krina K. Patel, May Daher, Ruby Delgado, Muzaffar H. Qazilbash, Stefan O. Ciurea, Yago Nieto, Issa F. Khouri, Samer A. Srour, Denái R. Milton, Robert Z. Orlowski, Richard E. Champlin, Hans C. Lee
Publikováno v:
Blood. 136:24-25
Introduction The role of upfront autologous stem cell transplantation (ASCT) for multiple myeloma (MM) has evolved over the last three decades, with significant improvements in preparative regimen, supportive care, induction, and maintenance therapy.
Autor:
Evandro D. Bezerra, Brenda M. Sandmaier, Linde M. Morsink, Megan Othus, H. Joachim Deeg, H. Gary Schoch, Brent L. Wood, Min Fang, Frederick R. Appelbaum, Roland B. Walter
Publikováno v:
Blood. 134:321-321
Background:Myeloablative allogeneic hematopoietic cell transplantation (HCT) is a common post-remission treatment strategy for medically fit adults with acute myeloid leukemia (AML) in morphologic remission. Several conditioning regimens have been ut
Autor:
Yuan-Shung Huang, Brian T. Fisher, Richard Aplenc, Karen R. Rabin, Kelly D. Getz, Jennifer J. Wilkes, Viviane C. Cahen, Yimei Li, Lena E. Winestone, Amanda M. DiNofia, M. Monica Gramatges, Alix E. Seif, Caitlin W Elgarten
Publikováno v:
Blood. 132:624-624
Administrative databases can be used to study outcomes including patients outside of clinical trials and have been used to identify relapse and HSCT in adult and adolescent/young adult leukemia populations. However, there are no published studies usi
Autor:
Matthew B. Siegel, Patrick J. Stiff, Aileen Go, Tulio E. Rodriguez, Brian Hess, Maria Theodorou, Michael Tallarico, Shams Bakhos, Scott E. Smith
Publikováno v:
Blood. 120:3102-3102
Abstract 3102 Identifying the optimal patients and timing for allogeneic hematopoietic stem cell transplant (HSCT) is an ongoing challenge for transplant centers that requires assessment of more than just the disease status and stage. Pre-existing co
Autor:
James L.M. Ferrara, Jochen Metzger, Arnold Ganser, Annika Krons, Hildegard T. Greinix, Ernst Holler, Gernot Beutel, Julia Kontsendorn, Michael Schleuning, Stefanie Buchholz, Anne M. Dickinson, N. Hahn, Hans-Jochem Kolb, Axel R. Zander, Eva Mischak-Weissinger
Publikováno v:
Blood. 114:347-347
Abstract 347 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for many hematologic malignancies or hematopoietic dysfunction syndromes, but the application is still limited due to major complications, such as sev
Autor:
Chatchada Karanes, Tang-Her Jaing, Stephen J. Forman, M. Graham, Ah Moy Tan, Patrick Tan, Brian Wang, Gretchen Eames, Auayporn Nademanee, Joseph Rosenthal, Hai Peng Lin, Lawrence Petz, David W. Gjertson, Tiffany Chow, Lee Lee Chan, Robert Chow, Tina Wu
Publikováno v:
Blood. 112:4406-4406
Unrelated cord blood (UCB) is an important stem cell source for unrelated hematopoietic cell transplantation of patients with non-malignant disorders. Cell dosage is a critical factor for successful UCB hematopoietic stem cell transplantation (HSCT).
Autor:
Susana Perdomo, Cecilia Guillermo, Lilián Díaz, Martha Nese, Alberto Baubeta, Laura Topolansky, Andrea Diaz, Mariana Stevenazzi, Ana Perdomo, Hugo Isaurralde, Graciela Lavagna, Juan Zunino
Publikováno v:
Blood. 108:5430-5430
Between 1995 and 2005, we performed 329 hematopoietic stem cell transplantation (HSCT), 286 autoulogous and 43 allogeneic. Long term results of treatment and outcome of ASCT in 100 Non Hodgkin Lymphoma (NHL) were analyzed. Median age was 47 years (ra